This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2007 by Grupo Gallego de Cancer de Pulmon.
Recruitment status was:  Recruiting
Information provided by:
Grupo Gallego de Cancer de Pulmon Identifier:
First received: April 25, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted

A open label non- randomized Phase II trial. It is anticipated that approximately 46 patients will be treated.


Primary: Objective response rate

Secondary: Progression free survival, Overall survival and Safety of Tarceva

Condition Intervention Phase
Non-Small Cell Lung Cancer Drug: Tarceva (erlotinib) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Tarceva Following Concurrent Chemo-Radiotherapy as First Line Therapy in Patients With Unresectable Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Grupo Gallego de Cancer de Pulmon:

Primary Outcome Measures:
  • Objective response rate

Secondary Outcome Measures:
  • Progression free survival
  • Overall survival
  • Safety of Tarceva

Estimated Enrollment: 46
Study Start Date: January 2006
Detailed Description:

Study Design: Phase II trial, open label, non-randomized and multicenter.

Expected total enrollment: 46

Study start: January, 2006

Study completation: January, 2008


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years.
  • Patients must have histologically confirmed diagnosis of non-small cell lung cancer, which is not surgically resectable (stage IA- IIIB).
  • Measurable disease.
  • Written informed consent must be obtained prior to the inclusion into the trial.
  • Karnofsky performance status of 80%.
  • Patients must have been treated with no prior chemotherapy or radioterapy.
  • Patients must have adequate bone marrow, liver and renal function.

    • Bone Marrow: WBC > 3000 x 103/mm3,
    • Platelets > 100 x 103/mm3,
    • Hgb > 10.0 gm/dl,
    • ANC >1500 x 103/mm3,
    • Hepatic:Bilirubin < 2 mg/dl (34 µmol/l); AST, ALT, and Alkaline Phosphatase < 5 x normal,
    • Renal:Creatinine < 1.5 mg/dl (132 µmol/l).

Exclusion Criteria:

  • Female patients who are pregnant or lactating.
  • Patients who have used other investigational agents within 21 days prior to study entry.
  • Patients who have received prior treatment with erlotinib or other anti-EGFR agent.
  • Significant comorbidity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00466284

Contact: Joaquin Casal, MD 986811111 ext 645

Grupo Gallego de Cancer de Pulmon Recruiting
Santiago de Compostela, A Coruña, Spain, 15701
Contact: Joaquin Casal, MD   
Sponsors and Collaborators
Grupo Gallego de Cancer de Pulmon
Principal Investigator: Joquin Casal, MD GGCP
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00466284     History of Changes
Other Study ID Numbers: GGCP023/05-ML19497
Study First Received: April 25, 2007
Last Updated: April 25, 2007

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on July 21, 2017